Recent studies on PD-L1/PD-1 have demonstrated that PD-L1 protein levels harbor dynamic changes in the development of the tumor, and corresponding expression changes also occur after immunotherapy, and these dynamic changes are partially regulated by posttranslational modifications (PTMs) (10). The gene discussed is RPL17; the disease is neoplasm.